Strategic Focus Target migraine market with STS101 as a novel DHE nasal powder for acute treatment, highlighting pre-commercial status and FDA approval to engage specialty care providers, hospitals, and neuro/ceph guidelines committees for early adoption.

Clinical Momentum Leverage recent and upcoming abstracts at the American Headache Society meetings to create partnership and sponsorship opportunities with academic centers, KOLs, and contract research organizations to accelerate clinical visibility and potential co-development or licensing discussions.

Strategic Partnerships Highlight SNBL collaboration and ownership changes to approach contract manufacturers, distribution partners, and patient access networks for co-marketing, global registration, and commercialization support in key regions.

Operational Readiness Position as a lean, specialty-focused organization with a demonstrated regulatory path and prep for pre-commercial launch activities, optimizing outreach to migraine clinics, urgent care centers, and specialty pharmacies for rapid uptake post-launch.

Financial Footing Frame revenue potential from a successful DHE-based acute treatment to engage investors and large pharma partners by mapping payer coverage, reimbursement pathways, and the value proposition against existing anti-migraine therapies.